Boosting protection for patients with non-acute cardiovascular disease: a focus on antithrombotic regimen (a consensus expert opinion from the Egyptian Society of Cardiology working group of thrombosis and prevention).

8.5%; hazard ratio [HR] 0.90, 95% CI 0.81–0.99) but a highly significant and clinically important large increases of major bleeding (2.2 vs. 1.0%; HR 2.32, 95% CI 1.82–2.94) and intracranial hemorrhage (0.7 vs. 0.5%; HR 1.71, 95% CI 1.18–2.48).

also in 132,142 other papers